- Medtronic (NYSE:MDT) will collaborate with Novo Nordisk (NYSE:NVO) to develop a system that integrates insulin dosing data from Novo's smart insulin pens into Medtronic's Continuous Glucose Monitoring (CGM) devices.
- Novo expects to launch its NovoPen 6 and NovoPen Echo Plus smart insulin pens in 2020, in addition to its disposable prefilled injection solution. The smart insulin pens will be compatible with both Android and iOS devices.
- Medtronic will update its CGM systems, including Guardian Connect, to accomodate Novo's NovoPen products.